Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study

BACKGROUND: Hepatitis C virus (HCV) is the primary contributor to chronic hepatic diseases. A rapid change in the situation took place with the advent of oral direct-acting antivirals (DAAs). However, a comprehensive review of the adverse event (AE) profile of the DAAs is lacking. This cross-section...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Marakby, Mai G., Solayman, Mohamed H., Sabri, Nagwa A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400676/
https://www.ncbi.nlm.nih.gov/pubmed/37227588
http://dx.doi.org/10.1007/s43441-023-00537-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400676/
https://www.ncbi.nlm.nih.gov/pubmed/37227588
http://dx.doi.org/10.1007/s43441-023-00537-x

Ejemplares similares